Global Microfluidic Immunoassay Market is expected to grow at a CAGR of 12.7% from 2019 to reach $2.01 billion by 2025, Says “Meticulous Research®”.
Microfluidic immunoassay is rapidly growing industry with potential of improving patient health in low-resource settings. POC tests are performed in critical-care settings, ambulatory centers, physician office laboratories, or at patient’s home. The POC industry is growing at a faster pace due to demographic shift and need for high throughput diagnosis in cost effective manner. However, many of the present POC devices need sample pre-treatment before conducting the test, produce variable results, and offer either qualitative, semi-quantitative or poor quantitative test results. This led to rising focus on achieving precise and quantitative results; and miniaturization of POC devices. Microﬂuidic systems (lab-on-a-chip) have attracted a great deal of attention as a miniaturized immunodiagnostic platform. Major advantages of LOC include consumption of small volumes of reagents and sample; and delivery of precise results with fast turnaround time.
Here are the top 10 companies operating in the microfluidic immunoassay market –
Abbott Laboratories (U.S.)
Incorporated in 1900 and headquartered at Chicago, Illinois, the U.S.; Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of wide range of health care products. Abbott Laboratories has four reportable segments: established pharmaceutical products, diagnostic products, nutritional products, and cardiovascular and neuromodulation products.
The company has strong presence in North America, Europe, Asia-Pacific, and rest of the world.
Quidel Corporation (U.S.)
Founded in 1979 as Monoclonal Antibodies, Inc. and re-incorporated as Quidel Corporation in 1987 with headquarters at California, the U.S.; Quidel Corporation offers rapid diagnostic testing solutions. The company operates through four business segments, namely cardiac immunoassays, rapid immunoassays, molecular diagnostic solutions, and specialized diagnostic solutions.
Through its subsidiaries and strong network of distributors, the company has presence across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Abaxis, Inc. (U.S.)
Founded in 1989 and headquartered at California, the U.S.; Abaxis, Inc. (a subsidiary of Zoetis Inc.) is engaged in developing, manufacturing, and marketing portable analytical systems with broad range of medical specialities in human and veterinary care. The company operates through two business segments, namely veterinary market and medical market.
Through its subsidiaries and strong distribution of network, the company has presence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Nanōmix, Inc. (U.S.)
Founded in 2000 and headquartered at Emeryville, California, the U.S.; Nanōmix, Inc. (formerly known as Covalent Materials, Inc.) develops analytical detection devices for the point of care diagnostic applications. The company provides Nanomix System (eLab) that includes a handheld reader, and an integrated assay cartridge with a carbon nanostructure biosensor.
Koninklijke Philips N.V. (the Netherlands)
Founded in 1891 and headquarteredat Amsterdam, the Netherlands. Koninklijke Philips N.V. operates as a health technology company. The company operates through five reportable business segments, namely personal health, diagnostic & treatment, connected care & health informatics, HealthTech other, and legacy items.
With more than 50 subsidiaries and strong network of distribution, the company has its presence across the world including the U.S., China, Germany, Japan, France, India, the Netherlands, and other.
Meticulous Research in its latest publication on global MICROFLUIDIC IMMUNOASSAY MARKET has predicted the growth of 12.7% during the forecast year 2019-2025.
Biosurfit SA (Portugal)
Founded in 2006, and headquartered in Azambuja, Portugal. Biosurfit SA is a diagnostics company focused on the development & manufacture of In-Vitro Diagnostic (IVD) tests for the Point-of-Care (POC) applications. The company has developed the spinit technology, which is the diagnostic system capable of performing POC blood tests (such as immunoassays, haematology, and clinical chemistry) on the same instrument.
Micropoint Bioscience, Inc. (U.S.)
Founded in 2006 and headquartered at California, the U.S.; Micropoint Bioscience, Inc. is engaged in providing rapid point-of-care diagnostics & self-test products & systems to medical professionals and patients. The company offers mLabs, an immunoassay diagnostic platform based on microfluidic technology; along with test cartridges for cardiac and inflammatory applications.
The company has its R&D facilities located in the headquarters itself, and the manufacturing facilities are located in Shenzhen, China. Also, the company has its European offices located in Grenoble, France.
Siloam Biosciences, Inc. (U.S.)
Founded in 2004 and headquartered at Ohio, the U.S.; Siloam Biosciences, Inc., is focused on developing next generation diagnostics & life sciences platform based on microfluidics technology. The company’s optimiser technology integrates the power of microfluidics into easy to use high medium & low-throughput platforms, as well as allows for the manual testing using the same assay disposables.
The company has its presence in North America, European Union, and the Asia-Pacific regions.
NanoEnTek Inc. (South Korea)
Founded in 2000 and headquartered at Seoul, South Korea. NanoEnTek Inc. offer life science experiment equipment, medical in-vitro diagnostic devices including point of care devices. The company is focusing on development of platforms based on lab-on-a-chip technology.
The company has major presence in the U.S., and Korea.
OPKO Health, Inc. (U.S.)
Founded in 1991 and headquartered at Florida, the U.S.; OPKO Health, Inc. was formed by the merger of eXegenics, Inc., Froptix Corporation, and Acuity Pharmaceuticals, Inc.; The company is a diversified healthcare company, managing their operations through two business segments, namely diagnostics and pharmaceuticals.
With its subsidiaries and strong network of distributors, the company has presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Amidst this crisis, Meticulous Research® is continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on this industry with Research PDF
Authoritative Research on the Microfluidic Immunoassay Market – Global Opportunity Analysis and Industry Forecast (2019-2025)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more: